Chris Martin, IASLC Media Relations | [email protected]
DENVER—November 16, 2021—Although the COVID-19 vaccines have been proven safe and effective in the general population, little is known about whether patients with lung cancer would develop a protective anti-spike antibody response because these patients were excluded from most COVID-19 vaccine trials. Previous studies demonstrated that patients with lung cancer suffered a 30% mortality rate from COVID-19 significantly higher than the general population.
In a new study published today in the Journal of Thoracic Oncology, researchers from France showed that SARS-CoV2 vaccines are safe and effective in patients with thoracic cancer, most of whom are immunized after two doses. A third shot given to 11% of patients with persistent low antibody titers resulted in an 88% immunization rate. The study was conducted by Valérie Gounant, MD and Gérard Zalcman, MD, PhD, from the University Hospital Bichat-Claude Bernard in Paris.
The researchers enrolled 306 patients with lung cancer, with a median age of 67.0 years. Of these, 283 patients received two vaccine doses at 28-day intervals. SARS-CoV2-spike antibodies were measured using Abbot ARCHITECT SARS-CoV-2 IgG immunoassay, prior to first injection of the mRNA vaccine, as well as after the fourth week, and two-to-16 weeks after second vaccine dose.
After 6.7-month median follow-up, only eight patients (2.6%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of 269 serological results available beyond
Day 14 post-second vaccine dose, 17 (6.3%) were still negative, while 34 (11 %) were < 300 AU/mL (12.5th percentile)—the threshold from which a perfect correlation was found between anti-S antibodies and neutralizing antibodies—using a pseudo-neutralization assay.
In multivariate analysis, only age, chemotherapy as last systemic treatment within 3 months, and chronic corticosteroid treatment were significantly associated with a lack of immunization. Thirty patients received a third vaccine dose, with only three patients showing persistent negative serology thereafter, whereas the others demonstrated clear seroconversion.
No anaphylaxis reaction occurred among the 306 patients, with 587 vaccine doses administered. Safety data were available for 278 patients (90.1%), without significant safety concerns.
“Although, this report involves, to the best our knowledge, the largest series of patients [with thoracic cancer] receiving anti-SARS-CoV-2 mRNA vaccines that has been published to date, the sample size of the different patient subsets remains limited,” the authors write.
About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the JTO
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.